Biodesix' VeriStrat test is covered by Cigna
Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.
VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).
Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Biodesix' Veristrat test is now covered by Highmark BCBS.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
AVEO and Biodesix announce a groundbreaking partnership on ficlatuzumab